{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:34:56Z","timestamp":1789763696579,"version":"4.0.1"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>The prevalence of chronic pain in patients with cancer ranges from 23% to 36%. Opioids are effective in relieving severe pain; however, they also cause side effects, such as physical dependence, tolerance, sedation, and hyperalgesia. The prevalence of opioid-induced constipation (OIC) increases with a rise in the duration of opioid analgesic use. When OIC develops, opioid treatment satisfaction decreases, and many patients tend to discontinue treatment. Naldemedine is an opioid receptor antagonist that improves OIC in patients with cancer by acting on the gastrointestinal tract. It does not inhibit opioid analgesia or cause withdrawal symptoms. Therefore, this review aims to provide a comprehensive overview of OIC management in patients with cancer pain, with a focus on naldemedine. This narrative review also reports recent findings on the efficacy and safety of naldemedine and provides comparisons based on cancer type. A comprehensive search was conducted to identify primary articles on the clinical effectiveness and adverse effects of naldemedine in patients with cancer with OIC. Naldemedine is a well-tolerated and effective drug for treatment of OIC in patients with cancer, and its use is expected to increase.<\/jats:p>","DOI":"10.1097\/md.0000000000043644","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T23:01:56Z","timestamp":1754089316000},"page":"e43644","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Naldemedine for the management of opioid-induced constipation in patients with cancer pain: A narrative review"],"prefix":"10.1097","volume":"104","author":[{"given":"Hiromi","family":"Nishiba","sequence":"first","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, Takasaki, Japan"},{"name":"Division of Pharmacy, Japan Community Health Care Organization (JCHO) Gunma Chuo Hospital, Maebashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-4255","authenticated-orcid":false,"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka-City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Nagamine","sequence":"additional","affiliation":[{"name":"Education Center for Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Education Center for Clinical Pharmacy, Faculty of Pharmacy, Takasaki University of Health and Welfare, Takasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Obayashi","sequence":"additional","affiliation":[{"name":"Graduate School of Pharmaceutical Sciences, Takasaki University of Health and Welfare, Takasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250918","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1097\/j.pain.0000000000000895","article-title":"Prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer.","volume":"158","author":"Bouhassira","year":"2017","journal-title":"Pain"},{"key":"R2-20250918","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/cancers15030591","article-title":"Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis.","volume":"15","author":"Snijders","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R3-20250918","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2407-8-177","article-title":"Depression and quality of life in cancer patients with and without pain: the role of pain beliefs.","volume":"8","author":"Tavoli","year":"2008","journal-title":"BMC Cancer"},{"key":"R4-20250918","doi-asserted-by":"crossref","first-page":"e00789","DOI":"10.1002\/prp2.789","article-title":"Addressing opioid tolerance and opioid-induced hypersensitivity: recent developments and future therapeutic strategies.","volume":"9","author":"Khan","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"R5-20250918","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects.","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician"},{"key":"R6-20250918","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/j.pain.0000000000000170","article-title":"Opioid-induced hyperalgesia in community-dwelling adults with chronic pain.","volume":"156","author":"Hooten","year":"2015","journal-title":"Pain"},{"key":"R7-20250918","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/pme.12724","article-title":"Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: laxative use, response, and symptom burden over time.","volume":"16","author":"Coyne","year":"2015","journal-title":"Pain Med"},{"key":"R8-20250918","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/CEOR.S61602","article-title":"Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review.","volume":"6","author":"Coyne","year":"2014","journal-title":"Clinicoecon Outcomes Res"},{"key":"R9-20250918","first-page":"S0016-5085(16)00222-5","article-title":"Bowel disorders.","volume":"16","author":"Mearin","year":"2016","journal-title":"Gastroenterology"},{"key":"R10-20250918","first-page":"427","article-title":"Cancer constipation: are opioids really the culprit?","volume":"16","author":"Davis","year":"2008","journal-title":"Support Care Cancer"},{"key":"R11-20250918","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/j.pain.0000000000002024","article-title":"Opioid-induced constipation in patients with cancer: a \u201creal-world,\u201d multicentre, observational study of diagnostic criteria and clinical features.","volume":"162","author":"Davies","year":"2021","journal-title":"Pain"},{"key":"R12-20250918","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.1002\/cam4.2341","article-title":"Incidence of opioid-induced constipation in Japanese patients with cancer pain: a prospective observational cohort study.","volume":"8","author":"Tokoro","year":"2019","journal-title":"Cancer Med"},{"key":"R13-20250918","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3344\/kjp.2019.32.2.69","article-title":"Opioid-induced constipation: a narrative review of therapeutic options in clinical management.","volume":"32","author":"Lang-Illievich","year":"2019","journal-title":"Korean J Pain"},{"key":"R14-20250918","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.SMJ.0000109215.54052.D8","article-title":"Incidence of constipation associated with long-acting opioid therapy: a comparative study.","volume":"97","author":"Staats","year":"2004","journal-title":"South Med J"},{"key":"R15-20250918","first-page":"CD011108","article-title":"Hydromorphone for cancer pain.","volume":"8","author":"Li","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"R16-20250918","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2165\/11634970-000000000-00000","article-title":"Opioid-induced bowel dysfunction: pathophysiology and management.","volume":"72","author":"Brock","year":"2012","journal-title":"Drugs"},{"key":"R17-20250918","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2050640618818305","article-title":"Pathophysiology and management of opioid-induced constipation: European expert consensus statement.","volume":"7","author":"Farmer","year":"2019","journal-title":"United Eur Gastroenterol J"},{"key":"R18-20250918","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1743-3150.2004.00553.x","article-title":"The opioid system in the gastrointestinal tract.","volume":"16","author":"Sternini","year":"2004","journal-title":"Neurogastroenterol Motil"},{"key":"R19-20250918","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-3-540-33823-9_2","article-title":"Opioids.","volume":"177","author":"Z\u00f6llner","year":"2007","journal-title":"Handb Exp Pharmacol"},{"key":"R20-20250918","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1073\/pnas.72.2.590","article-title":"Morphine receptors as regulators of adenylate cyclase activity.","volume":"72","author":"Sharma","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R21-20250918","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1743-3150.2004.00554.x","article-title":"Function of opioids in the enteric nervous system.","volume":"16","author":"Wood","year":"2004","journal-title":"Neurogastroenterol Motil"},{"key":"R22-20250918","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/AJP.0000000000000852","article-title":"Opioid-induced constipation: a review of health-related quality of life, patient burden, practical clinical considerations, and the impact of peripherally acting \u03bc-opioid receptor antagonists.","volume":"36","author":"Argoff","year":"2020","journal-title":"Clin J Pain"},{"key":"R23-20250918","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1191\/026921698674125048","article-title":"The relationship between opioid use and laxative use in terminally ill cancer patients.","volume":"12","author":"Sykes","year":"1998","journal-title":"Palliat Med"},{"key":"R24-20250918","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1).","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med"},{"key":"R25-20250918","first-page":"687","article-title":"Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy.","volume":"27","author":"Fine","year":"2019","journal-title":"Support Care Cancer"},{"key":"R26-20250918","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1177\/1756283X15589526","article-title":"Evolving paradigms in the treatment of opioid-induced bowel dysfunction.","volume":"8","author":"Poulsen","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"key":"R27-20250918","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1365-2036.2008.03689.x","article-title":"Gastrointestinal side effects in chronic opioid users: results from a population-based survey.","volume":"27","author":"Cook","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-20250918","first-page":"131","article-title":"Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose.","volume":"21","author":"Wirz","year":"2012","journal-title":"Eur J Cancer Care (Engl)"},{"key":"R29-20250918","first-page":"7577","article-title":"Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation.","volume":"29","author":"Lemaire","year":"2021","journal-title":"Support Care Cancer"},{"key":"R30-20250918","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2147\/JPR.S160488","article-title":"Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain.","volume":"11","author":"Webster","year":"2018","journal-title":"J Pain Res"},{"key":"R31-20250918","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/pharmacy12020048","article-title":"A systematic review of naldemedine and naloxegol for the treatment of opioid-induced constipation in cancer patients.","volume":"12","author":"Braun","year":"2024","journal-title":"Pharmacy (Basel)"},{"key":"R32-20250918","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s40265-019-01160-7","article-title":"Naldemedine: a review in opioid-induced constipation.","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"R33-20250918","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.15791","article-title":"Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation.","volume":"52","author":"Vijayvargiya","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"R34-20250918","first-page":"e16201","article-title":"Efficacy and safety of peripherally acting \u03bc-opioid receptor antagonist (PAMORAs) for the management of patients with opioid-induced constipation: a systematic review.","volume":"13","author":"Rekatsina","year":"2021","journal-title":"Cureus"},{"key":"R35-20250918","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2147\/DDDT.S221278","article-title":"The use of peripheral \u03bc-opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: an update on their efficacy and safety.","volume":"14","author":"Pergolizzi","year":"2020","journal-title":"Drug Des Devel Ther"},{"key":"R36-20250918","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/2050640615604543","article-title":"Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response.","volume":"3","author":"Tack","year":"2015","journal-title":"United Eur Gastroenterol J"},{"key":"R37-20250918","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1200\/JCO.24.00381","article-title":"Naldemedine for opioid-induced constipation in patients with cancer: a multicenter, double-blind, randomized, placebo-controlled trial.","volume":"42","author":"Hamano","year":"2024","journal-title":"J Clin Oncol"},{"key":"R38-20250918","doi-asserted-by":"crossref","first-page":"118048","DOI":"10.1016\/j.lfs.2020.118048","article-title":"Preventive effects of naldemedine, peripherally acting \u03bc-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.","volume":"257","author":"Kanemasa","year":"2020","journal-title":"Life Sci"},{"key":"R39-20250918","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/pm\/pnw325","article-title":"A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain.","volume":"18","author":"Webster","year":"2017","journal-title":"Pain Med"},{"key":"R41-20250918","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/jpet.119.264515","article-title":"Pharmacological profile of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist: comparison with naloxone and naloxegol.","volume":"373","author":"Kanemasa","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"R42-20250918","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.dmpk.2018.12.002","article-title":"Minimal contribution of P-gp on the low brain distribution of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist.","volume":"34","author":"Watari","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"key":"R43-20250918","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ajgsup.2014.5","article-title":"Molecular physiology of enteric opioid receptors.","volume":"2","author":"Galligan","year":"2014","journal-title":"Am J Gastroenterol Suppl"},{"key":"R44-20250918","doi-asserted-by":"crossref","first-page":"e13563","DOI":"10.1111\/nmo.13563","article-title":"Pharmacologic effects of naldemedine, a peripherally acting \u03bc-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.","volume":"31","author":"Kanemasa","year":"2019","journal-title":"Neurogastroenterol Motil"},{"key":"R45-20250918","doi-asserted-by":"crossref","first-page":"17562848221078638","DOI":"10.1177\/17562848221078638","article-title":"Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain.","volume":"15","author":"BouSaba","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"R46-20250918","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cpdd.690","article-title":"The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of naldemedine.","volume":"9","author":"Fukumura","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R47-20250918","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40261-020-00902-w","article-title":"Clinical drug-drug interaction studies to evaluate the effects of a p-glycoprotein inhibitor, CYP3A inhibitors, and a CYP3A inducer on the pharmacokinetics of naldemedine in healthy subjects.","volume":"40","author":"Fukumura","year":"2020","journal-title":"Clin Drug Investig"},{"key":"R48-20250918","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/jcpt.12812","article-title":"Treating opioid-induced constipation in patients taking other medications: avoiding CYP450 drug interactions.","volume":"44","author":"Raffa","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"R49-20250918","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2016.70.8453","article-title":"Phase IIb, randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer.","volume":"35","author":"Katakami","year":"2017","journal-title":"J Clin Oncol"},{"key":"R50-20250918","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer.","volume":"35","author":"Katakami","year":"2017","journal-title":"J Clin Oncol"},{"key":"R51-20250918","first-page":"3943","article-title":"Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.","volume":"30","author":"Takata","year":"2022","journal-title":"Support Care Cancer"},{"key":"R52-20250918","first-page":"504","article-title":"The safety and effectiveness of naldemedine for opioid-induced constipation in patients with advanced cancer in real-world palliative care settings: a multicenter prospective observational study.","volume":"32","author":"Shimizu","year":"2024","journal-title":"Support Care Cancer"},{"key":"R53-20250918","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3390\/cancers14092112","article-title":"Effectiveness of naldemedine compared with magnesium oxide in preventing opioid-induced constipation: a randomized controlled trial.","volume":"14","author":"Ozaki","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R54-20250918","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1089\/jpm.2022.0495","article-title":"Efficacy and safety of naldemedine administration for opioid-induced constipation in cancer patients with poor performance status.","volume":"26","author":"Fujita","year":"2023","journal-title":"J Palliat Med"},{"key":"R55-20250918","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12876-020-1173-z","article-title":"Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.","volume":"20","author":"Takagi","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"R56-20250918","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/medicina57111233","article-title":"Real-world patient characteristics and treatment patterns of naldemedine for the treatment of opioid-induced constipation in patients with cancer: a multicenter retrospective chart review study.","volume":"57","author":"Hiruta","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"R57-20250918","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.3390\/jcm11092672","article-title":"Efficacy and safety of naldemedine for patients with cancer with opioid-induced constipation in clinical practice: a real-world retrospective study.","volume":"11","author":"Nishiba","year":"2022","journal-title":"J Clin Med"},{"key":"R58-20250918","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/cpdd.387","article-title":"Phase 1, randomized, double-blind, placebo-controlled studies on the safety, tolerability, and pharmacokinetics of naldemedine in healthy volunteers.","volume":"7","author":"Fukumura","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"R59-20250918","first-page":"e46090","article-title":"Real- world evidence for the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain: post-hoc subgroup analysis of post-marketing surveillance in Japan.","volume":"15","author":"Naya","year":"2023","journal-title":"Cureus"},{"key":"R60-20250918","doi-asserted-by":"crossref","first-page":"e000527","DOI":"10.1136\/esmoopen-2019-000527","article-title":"Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies.","volume":"4","author":"Osaka","year":"2019","journal-title":"ESMO Open"},{"key":"R61-20250918","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.3390\/jcm12226997","article-title":"Influence of brain metastasis on analgesia-related outcomes in patients with lung and breast cancers treated with naldemedine: a propensity score-matched analysis.","volume":"12","author":"Hanamoto","year":"2023","journal-title":"J Clin Med"},{"key":"R62-20250918","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1017\/S147895152200044X","article-title":"Opioid withdrawal syndrome developing after long-term administration of naldemedine.","volume":"20","author":"Ishida","year":"2022","journal-title":"Palliat Support Care"},{"key":"R63-20250918","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1017\/S1478951521001917","article-title":"Naldemedine-induced opioid withdrawal syndrome with severe psychiatric symptoms in an advanced cervical cancer patient without brain metastasis.","volume":"20","author":"Ishida","year":"2022","journal-title":"Palliat Support Care"},{"key":"R64-20250918","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2169\/internalmedicine.3098-19","article-title":"Naldemedine-induced opioid withdrawal syndrome in a patient with breast cancer without brain metastasis.","volume":"59","author":"Ishii","year":"2020","journal-title":"Intern Med"},{"key":"R65-20250918","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1017\/S1478951523000858","article-title":"Naldemedine-induced opioid withdrawal with restlessness as the predominant symptom in a palliative care setting.","volume":"21","author":"Sato","year":"2023","journal-title":"Palliat Support Care"},{"key":"R66-20250918","first-page":"CD006332","article-title":"Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.","volume":"6","author":"Candy","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R67-20250918","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1111\/1759-7714.14557","article-title":"A retrospective study of the efficacy and safety of naldemedine for opioid-induced constipation in thoracic cancer patients.","volume":"13","author":"Imai","year":"2022","journal-title":"Thorac Cancer"},{"key":"R68-20250918","doi-asserted-by":"crossref","first-page":"697","DOI":"10.21037\/apm-22-1130","article-title":"Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: a retrospective analysis.","volume":"12","author":"Nishiba","year":"2023","journal-title":"Ann Palliat Med"},{"key":"R69-20250918","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3390\/medicina59030492","article-title":"A retrospective study of the efficacy and safety of naldemedine for treatment of opioid-induced constipation in patients with hepatobiliary pancreatic cancer.","volume":"59","author":"Kamiya","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"R70-20250918","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40266-016-0381-2","article-title":"Constipation in elderly patients with noncancer pain: focus on opioid-induced constipation.","volume":"33","author":"Chokhavatia","year":"2016","journal-title":"Drugs Aging"},{"key":"R71-20250918","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s40266-020-00753-2","article-title":"Safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy: a subgroup analysis of patients \u2265 65 years of age.","volume":"37","author":"Wild","year":"2020","journal-title":"Drugs Aging"},{"key":"R72-20250918","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/MEG.0000000000002746","article-title":"Efficacy and safety of naldemedine for opioid-induced constipation in older patients with cancer: a retrospective study.","volume":"36","author":"Imai","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R73-20250918","first-page":"292","article-title":"Clinical outcomes of intravenous methylnaltrexone in children: a single-arm retrospective cohort study.","volume":"29","author":"Raschka","year":"2024","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R74-20250918","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-0041-1736335","article-title":"Successful use of intravenous methylnaltrexone for opioid-induced constipation in critically ill pediatric patients.","volume":"13","author":"Mills","year":"2024","journal-title":"J Pediatr Intensive Care"},{"key":"R75-20250918","first-page":"136","article-title":"Methylnaltrexone for opioid-induced dysmotility in critically ill infants and children: a pilot study.","volume":"28","author":"Smith","year":"2023","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R76-20250918","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/pbc.24615","article-title":"Methylnaltrexone for opioid-induced constipation in pediatric oncology patients.","volume":"60","author":"Rodrigues","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"R77-20250918","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/00099228221142129","article-title":"Naloxegol for treatment of opioid-induced constipation in the pediatric intensive care unit.","volume":"62","author":"Gillett","year":"2023","journal-title":"Clin Pediatr (Phila)"},{"key":"R78-20250918","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1089\/jpm.2024.0018","article-title":"Efficacy safety of naldemedine for opioid-induced constipation in children.","volume":"27","author":"Miura","year":"2024","journal-title":"J Palliat Med"},{"key":"R79-20250918","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/fcp.12976","article-title":"Impacts of genetic polymorphisms and cancer cachexia on naldemedine pharmacokinetics and bowel movements in patients receiving opioid analgesics.","volume":"38","author":"Nakatsugawa","year":"2024","journal-title":"Fundam Clin Pharmacol"},{"key":"R80-20250918","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American Gastroenterological Association Institute Guideline on the medical management of opioid-induced constipation.","volume":"156","author":"Crockett","year":"2019","journal-title":"Gastroenterology"},{"key":"R81-20250918","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1089\/jpm.2021.0438","article-title":"Revision of pharmacological treatment recommendations for cancer pain: clinical guidelines from the Japanese society of palliative medicine.","volume":"25","author":"Mawatari","year":"2022","journal-title":"J Palliat Med"},{"key":"R82-20250918","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1248\/bpb.b23-00487","article-title":"A retrospective observational study of factors affecting the efficacy of concurrent prescription of naldemedine for opioid-induced constipation caused by oxycodone tablets.","volume":"46","author":"Yamada","year":"2023","journal-title":"Biol Pharm Bull"},{"key":"R83-20250918","first-page":"1083","article-title":"A preliminary study of the effect of naldemedine tosylate on opioid-induced nausea and vomiting.","volume":"28","author":"Sato","year":"2020","journal-title":"Support Care Cancer"},{"key":"R84-20250918","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1248\/bpb.b21-00474","article-title":"Involvement of the peripheral \u03bc-opioid receptor in tramadol-induced constipation in rodents.","volume":"44","author":"Yasufuku","year":"2021","journal-title":"Biol Pharm Bull"},{"key":"R85-20250918","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/jjco\/hyae135","article-title":"Effect of add-on naldemedine treatment in patients with cancer and opioid-induced constipation insufficiently responding to magnesium oxide: a pooled, subgroup analysis of two randomized controlled trials.","volume":"55","author":"Kessoku","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"R86-20250918","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/phar.2658","article-title":"Use of naldemedine is associated with reduced incidence of hyperactive delirium in cancer patients with opioid-induced constipation: a nationwide retrospective cohort study in Japan.","volume":"42","author":"Abe","year":"2022","journal-title":"Pharmacotherapy"},{"key":"R87-20250918","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/s41416-022-01928-x","article-title":"Possible mechanism for improving the endogenous immune system through the blockade of peripheral \u03bc-opioid receptors by treatment with naldemedine.","volume":"127","author":"Gondoh","year":"2022","journal-title":"Br J Cancer"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:02:14Z","timestamp":1758232934000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000043644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":86,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043644","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}